<DOC>
	<DOCNO>NCT00438204</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed disodium may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving pemetrexed disodium gemcitabine together bevacizumab may kill tumor cell . PURPOSE : This phase II trial study well give pemetrexed disodium gemcitabine together bevacizumab work treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Pemetrexed Disodium , Gemcitabine , Bevacizumab Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy pemetrexed disodium , gemcitabine hydrochloride , bevacizumab chemotherapy-naïve patient stage IIIB IV nonsquamous cell non-small cell lung cancer . Secondary - Determine response rate patient treat regimen . - Determine time treatment failure patient treat regimen . - Determine overall survival patient treat regimen . - Determine toxicity regimen patient . OUTLINE : Patients receive pemetrexed disodium IV 10 minute , gemcitabine hydrochloride IV 30 minute , bevacizumab IV 30-90 minute day 1 . Treatment repeat every 14 day 12 course absence disease progression unacceptable toxicity . Patients may receive bevacizumab alone absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 6 month . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion Criteria Histologic cytologic proof nonsquamous nonsmall cell lung cancer ( NSCLC ) ( adenocarcinoma , bronchioloalveolar , large cell carcinoma ) . Must Stage IV IIIB NSCLC . Patients Stage IIIB must pleural effusion candidate treatment locally advanced disease chemoradiotherapy . Can tumor cavitation.. Have unidimensional measurable evaluable disease . If disease within previous radiation port must document progression . 18 year age life expectancy great 12 week . Must prior chemotherapy advanced disease . Must ECOG performance status 01 . With treated brain metastasis eligble . detail . Adequate organ function : Absolute neutrophil count &gt; 1.5 x 109/L Platelet count &gt; 100,000/109/L Hemoglobin &gt; 8g/dl Calculated creatinine clearance &gt; 45mL/min use standard Cockroft Gault formula Hepatic : bilirubin &lt; 1.5 time upper limit normal , alkaline phosphatase , aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; 3 time upper limit normal . Alkaline phosphatase , AST , ALT &lt; 5 time upper limit normal acceptable liver tumor involvement . Urine protein : creatinine ratio ≤1.0 screening Patients reproductive potential must use approved contraceptive method 3 month study . Must sign inform consent detail investigational nature study accord institutional federal guideline . Registered clinical trial office institution . Exclusion Criteria Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored bevacizumab cancer study Prior chemotherapy except erlotinib advanced disease . Uncontrolled hypertension ( Blood pressure &gt; 150/100 mmHg ) Unstable angina New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix E ) History myocardial infarction within 6 month prior day 1 History hemorrhagic thrombotic stroke CNS bleed within 6 month prior day 1 Clinically significant peripheral vascular disease 61 Evidence bleed diathesis coagulopathy . Patients must require full dose anticoagulant reason . Known CNS disease , except treat brain metastasis Treated brain metastasis define evidence progression hemorrhage treatment ongoing requirement dexamethasone , ascertain clinical examination brain imaging ( MRI CT ) screen period . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Minor surgical procedure fine needle aspiration core biopsy within 7 day prior Day 0 Urine protein : creatinine ratio &gt; = 1.0 screen History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 Serious , nonhealing wound , ulcer , bone fracture Evidence cavitation tumor . Intrathoracic lung carcinoma squamous cell histology Mixed tumor categorize predominant cell type unless small cell element present , case patient ineligible ; sputum cytology alone unacceptable . Extrathoraciconly squamous cell NSCLC eligible . Patients peripheral lung lesion ( NSCLC histology ) also eligible . History hemoptysis ( bright red blood 1/2 teaspoon within 28 day registration clinical history &gt; Grade 2 Clinically significant effusion drain Inability comply study and/or followup procedure Previous concurrent malignancy exception adequately treat squamous cell basal cell carcinoma skin , situ carcinoma cervix , malignancy treat clinical remission 3 year . Prior radiation therapy target lesion , unless lesion clearly progress interval recent radiation therapy enrollment least 4 week . Pregnancy lactate female . All premenopausal woman negative urine pregnancy test prior enrollment . All patient reproductive potential agree use effective contraceptive method . Serious concomitant systemic disorder ( include oncologic emergency ) incompatible study ( discretion investigator ) . Inability interrupt nonsteroidal antiinflammatory agent 2 day , day , 2 day dose pemetrexed . Disease radiologically image . Inability take dexamethasone , folic acid vitamin B12 administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>